113 related articles for article (PubMed ID: 32103523)
1. Pivotal cytokines and their transcription factors are the targets of guluronic acid (G2013) for inhibiting the immunopathogenesis process of multiple sclerosis.
Hossein-Khannazer N; Shabani S; Farokhfar M; Azizi G; Asarzadegan F; Safarpour Lima B; Mirshafeiey A
Drug Dev Res; 2020 Jun; 81(4):511-516. PubMed ID: 32103523
[TBL] [Abstract][Full Text] [Related]
2. Effect of Guluronic Acid (G2013), As a New Anti-inflammatory Drug on Gene Expression of Pro-inflammatory and Anti-inflammatory Cytokines and Their Transcription Factors in Rheumatoid Arthritis Patients.
Bakhtiari T; Azarian S; Ghaderi A; Ahmadzadeh A; Mirshafiey A
Iran J Allergy Asthma Immunol; 2019 Nov; 18(6):639-648. PubMed ID: 32245307
[TBL] [Abstract][Full Text] [Related]
3. Immunomodulatory Effect of G2013 (α-L-Guluronic Acid) on the TLR2 and TLR4 in Human Mononuclear Cells.
Sharifi L; Mohsenzadegan M; Aghamohammadi A; Rezaei N; Zavareh FT; Bokaie S; Moshiri M; Aghazadeh Z; Norouzbabaie Z; Azizi G; Mirshafiey A
Curr Drug Discov Technol; 2018; 15(2):123-131. PubMed ID: 28578651
[TBL] [Abstract][Full Text] [Related]
4. Assessment of immunological profile in ankylosing spondylitis patients following a clinical trial with guluronic acid (G2013), as a new NSAID with immunomodulatory properties.
Mortazavi-Jahromi SS; Nazeri S; Jafarnezhad-Ansariha F; Oraei M; Mirshafiey A
Immunol Res; 2019 Feb; 67(1):108-115. PubMed ID: 30474833
[TBL] [Abstract][Full Text] [Related]
5. The effects of guluronic acid (G2013), a new emerging treatment, on inflammatory factors in nonalcoholic steatohepatitis patients under
Tahmasebi S; Neishaboori H; Jafari D; Faghihzadeh E; Esmaeilzadeh A; Mirshafiey A
Immunopharmacol Immunotoxicol; 2021 Oct; 43(5):562-570. PubMed ID: 34314306
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the oral administration of α-l-guluronic acid on COX-1 and COX-2 gene expression profile in ankylosing spondylitis patients.
Sadoughi A; Mansouri R; Nazeri S; Mirshafiey A
Drug Dev Res; 2021 Apr; 82(2):296-301. PubMed ID: 33140463
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the Effect of α-L-Guluronic Acid (G2013) on COX-1, COX-2 Activity and Gene Expression for Introducing this Drug as a Novel NSAID with Immunomodulatory Property.
Mirshafiey A; Mortazavi-Jahromi SS; Taeb M; Cuzzocrea S; Esposito E
Recent Pat Inflamm Allergy Drug Discov; 2018; 12(2):162-168. PubMed ID: 29879894
[TBL] [Abstract][Full Text] [Related]
8. Effects of guluronic acid (G2013) on gene expression of TLR2, TLR4, MyD88, TNF-α and CD52 in multiple sclerosis under in vitro conditions.
Noorbakhsh SM; Razavi A; Moghadam NB; Saadat P; Hoseini M; Aghazadeh Z; Mobini M; Oraei M; Mirshafiey A
Immunopharmacol Immunotoxicol; 2019 Dec; 41(6):586-590. PubMed ID: 31594427
[No Abstract] [Full Text] [Related]
9. Effects of guluronic acid, as a new NSAID with immunomodulatory properties on IL-17, RORγt, IL-4 and GATA-3 gene expression in rheumatoid arthritis patients.
Khadem Azarian S; Jafarnezhad-Ansariha F; Nazeri S; Azizi G; Aghazadeh Z; Hosseinzadeh E; Mirshafiey A
Immunopharmacol Immunotoxicol; 2020 Feb; 42(1):22-27. PubMed ID: 31856612
[No Abstract] [Full Text] [Related]
10. Evaluation of G2013 (α-L-guluronic acid) efficacy on PC-3 cells through inhibiting the expression of inflammatory factors.
Bagherian Z; Mirshafiey A; Mohsenzadegan M; Farajollahi MM
Clin Exp Pharmacol Physiol; 2022 Feb; 49(2):254-263. PubMed ID: 34699087
[TBL] [Abstract][Full Text] [Related]
11. An in vitro evaluation of anti-aging effect of guluronic acid (G2013) based on enzymatic oxidative stress gene expression using healthy individuals PBMCs.
Taeb M; Mortazavi-Jahromi SS; Jafarzadeh A; Mirzaei MR; Mirshafiey A
Biomed Pharmacother; 2017 Jun; 90():262-267. PubMed ID: 28364598
[TBL] [Abstract][Full Text] [Related]
12. Effects of guluronic acid (G2013) on SHIP1, SOCS1 induction and related molecules in TLR4 signaling pathway.
Mortazavi-Jahromi SS; Farazmand A; Motamed N; Navabi SS; Mirshafiey A
Int Immunopharmacol; 2018 Feb; 55():323-329. PubMed ID: 29310108
[TBL] [Abstract][Full Text] [Related]
13. The Immunomodulatory Role of G2013 (α-L-Guluronic Acid) on the Expression of TLR2 and TLR4 in HT29 cell line.
Farhang H; Sharifi L; Dallal MMS; Moshiri M; Norouzbabaie Z; Bokaie S; Aletaha S; Zargar SJ; Mirshafiey A
Curr Drug Discov Technol; 2019; 16(1):91-95. PubMed ID: 29484999
[TBL] [Abstract][Full Text] [Related]
14. Antagonistic Property of G2013 (α-L-Guluronic Acid) on Gene Expression of MyD88, Tollip, and NF-κB in HEK293 TLR2 and HEK293 TLR4.
Sharifi L; Aghamohammadi A; Aletaha S; Bigdeli R; Asgary V; Bokaie S; Asgardoon MH; Azizi G; Mirshafiey A
Endocr Metab Immune Disord Drug Targets; 2019; 19(2):144-149. PubMed ID: 30784390
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of β-D-Mannuronic Acid [M2000] on the Pro-Apoptotic Process and Inflammatory-Related Molecules NFκB, IL-8 and Cd49d using Healthy Donor PBMC.
Khalatbari A; Mahdavi M; Jafarnezhad F; Afraei S; Zavareh FT; Aghazadeh Z; Ghaderi A; Mirshafiey A
Curr Drug Discov Technol; 2020; 17(2):225-232. PubMed ID: 30417790
[TBL] [Abstract][Full Text] [Related]
16. pSTAT1, pSTAT3, and T-bet expression in peripheral blood mononuclear cells from relapsing-remitting multiple sclerosis patients correlates with disease activity.
Frisullo G; Angelucci F; Caggiula M; Nociti V; Iorio R; Patanella AK; Sancricca C; Mirabella M; Tonali PA; Batocchi AP
J Neurosci Res; 2006 Oct; 84(5):1027-36. PubMed ID: 16865709
[TBL] [Abstract][Full Text] [Related]
17. The effect of retinyl-palmitate on the level of pro and anti-inflammatory cytokines in multiple sclerosis patients: A randomized double blind clinical trial.
Bitarafan S; Mohammadpour Z; Jafarirad S; Harirchian MH; Yekaninejad MS; Saboor-Yaraghi AA
Clin Neurol Neurosurg; 2019 Feb; 177():101-105. PubMed ID: 30640138
[TBL] [Abstract][Full Text] [Related]
18. Reduction of both pro- and anti-inflammatory cytokines after 6 months of interferon beta-1a treatment of multiple sclerosis.
Khademi M; Wallström E; Andersson M; Piehl F; Di Marco R; Olsson T
J Neuroimmunol; 2000 Mar; 103(2):202-10. PubMed ID: 10696916
[TBL] [Abstract][Full Text] [Related]
19. Clinical response to glatiramer acetate correlates with modulation of IFN-gamma and IL-4 expression in multiple sclerosis.
Valenzuela RM; Costello K; Chen M; Said A; Johnson KP; Dhib-Jalbut S
Mult Scler; 2007 Jul; 13(6):754-62. PubMed ID: 17613604
[TBL] [Abstract][Full Text] [Related]
20. The effect of season on cytokine expression in multiple sclerosis and healthy subjects.
Stewart N; Taylor B; Ponsonby AL; Pittas F; van der Mei I; Woods G; Walters H
J Neuroimmunol; 2007 Aug; 188(1-2):181-6. PubMed ID: 17628701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
